------------------------DOSAGE AND ADMINISTRATION---------------------Rheumatoid Arthritis  Recommended dose of XELJANZ is 5 mg twice daily. (2.1)  Moderate and severe renal impairment and moderate hepatic impairme

First Page		Document Content
Date: 2015-06-22 13:44:18 Medicine Clinical medicine Immunosuppressants Tuberculosis Tofacitinib Azathioprine Tuberculosis management Latent tuberculosis Anakinra Alefacept		------------------------DOSAGE AND ADMINISTRATION---------------------Rheumatoid Arthritis  Recommended dose of XELJANZ is 5 mg twice daily. (2.1)  Moderate and severe renal impairment and moderate hepatic impairme Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 584,71 KB Share Document on Facebook

	------------------------DOSAGE AND ADMINISTRATION---------------------Rheumatoid Arthritis  Recommended dose of XELJANZ is 5 mg twice daily. (2.1)  Moderate and severe renal impairment and moderate hepatic impairme DocID: 1m0Le - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COSENTYX safely and effectively. See full prescribing information for COSENTYX. ---------------------------------CO DocID: UPmN - View Document
	Horizon Scanning Technology Prioritising Summary Home ultraviolet B (UVB) phototherapy for the treatment of severe psoriasis March 2010 DocID: SMK1 - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION DocID: RJk3 - View Document
	achanA September 12, 2007 Astellas Initiates Phase II Clinical Trials for Immunosuppressant, ASP0485 DocID: M3jp - View Document